Reported Late Tuesday April 4, Celyad Oncology Announces Receipt Of Nasdaq Notice Informing The Company That It Failed To Maintain The Continued Listing Requirement Under Nasdaq Listing Rule 5450(b)(1)(A)

Celyad Oncology ((Euronext &, NASDAQ:CYAD) (the "Company"), a biotechnology company focused on innovative technologies for chimeric antigen receptor (CAR) T-cell therapies, received a letter (the "Letter") on March 31, 2023 from The Nasdaq Stock Market ("Nasdaq") informing the Company that it failed to maintain the continued listing requirement under Nasdaq Listing Rule 5450(b)(1)(A) for the Nasdaq Global Market, which requires that a listed company's stockholders' equity be at least $10.0 million (the "Stockholders' Equity Requirement").
 

Based upon the reported stockholders' equity of approximately $4.6 million in the Company's Form 20-F for the period ended December 31, 2022, the Company did not meet the Stockholders' Equity Requirement.

The Company has a period of 45 calendar days from the date of the Letter, or until May 15, 2023, to submit a plan to regain compliance with the Stockholders' Equity Requirement. If such a plan is submitted and accepted, Nasdaq may grant an extension of up to 180 calendar days from the date of the Letter for the Company to regain compliance.

The Letter has no immediate effect on the listing or trading of the Company's American Depositary Shares representing ordinary shares ("ADSs"), which will continue to be listed on Nasdaq during this period, subject to the Company's compliance with other listing standards, under the symbol "CYAD".